½ÃÀ庸°í¼­
»óǰÄÚµå
1384301

¼¼°è Æ®¶ó¸¶µ¹(Tramadol) ¾à¹° ½ÃÀå - Åõ¾à ÇüÅÂ, Åõ¿© °æ·Î, À¯Åë ä³Îº° ¿¹Ãø(2023-2032³â)

Tramadol Drug Market - By Dosage Form (Tablet, Capsule, Liquid, Suspension), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Global Forecast, 2023-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Æ®¶ó¸¶µ¹ ¾à¹° ½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2032³â¿¡ °ÉÃÄ CAGR 6.5% ÀÌ»óÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÁÖ¿ä ¿äÀÎÀº ¸¸¼º ÅëÁõ ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ¼¼°èÀÇ °í·ÉÈ­ Àα¸ Áõ°¡ÀÔ´Ï´Ù.

2022³â¿¡´Â ¼¼°è¿¡¼­ 65¼¼ ÀÌ»óÀÇ Àα¸°¡ 7¾ï 7,100¸¸ ¸í °¡±îÀÌ¿¡ À̸£·¶À¸¸ç, ÀÌ´Â ÃÑ Àα¸ÀÇ °ÅÀÇ 10%¿¡ ÇØ´çÇÕ´Ï´Ù. ÀÌ ºñÀ²Àº 2050³â¿¡´Â ¼¼°è Àα¸ÀÇ ¾à 16%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÅëÁõ °ü¸® ¿ä¹ý¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó, Æ®¶ó¸¶µ¹Àº °Ç°­ °ü¸® °ü°èÀÚ¿Í È¯ÀÚµé »çÀÌ¿¡¼­ ¼±È£ÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Áï¹æ¼º Á¦Çü°ú ¼­¹æ¼º Á¦ÇüÀ» ¸ðµÎ Á¦°øÇÏ´Â ÀÌ ¾àÁ¦ÀÇ ´Ù¿ëµµ´Â ´Ù¾çÇÑ °íÅëÀÇ °­µµ¿¡ ÇØ´çÇÏ´Â ±ÍÁßÇÑ µµ±¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. °Ç°­ °ü¸® Á¦°ø¾÷ü°¡ ȯÀÚ °á°ú¸¦ °³¼±ÇÏ°í ¿ÀÇÇ¿ÀÀÌµå °ü·Ã À§ÇèÀ» ÃÖ¼ÒÈ­ÇÏ·Á°í ³ë·ÂÇÏ´Â µ¿¾ÈÀÌ Á¦Ç°ÀÇ µ¶Æ¯ÇÑ ÇÁ·ÎÆÄÀÏÀº ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Æ®¶ó¸¶µ¹ ¾à¹°¹° »ê¾÷Àº Åõ¾à ÇüÅÂ, Åõ¿© °æ·Î, À¯Åë ä³Î ¹× Áö¿ª¿¡ µû¶ó ºÐ·ùµË´Ï´Ù.

ĸ½¶Àº ó¹æÀÚ¿Í È¯ÀÚ ¸ðµÎ¿¡°Ô ¼±È£µÇ´Â ¿É¼ÇÀ̱⠶§¹®¿¡ 2032³â±îÁö Å« ¼ö¿ä°¡ ¿¹»óµË´Ï´Ù. ĸ½¶Àº Æ®¶ó¸¶µ¹ÀÇ Æí¸®Çϰí È¿°úÀûÀÎ Åõ¿© ¼ö´ÜÀ» Á¦°øÇÏ¿© Á¤È®ÇÑ Åõ¿©¿Í »ç¿ë ÆíÀǼºÀ» º¸ÀåÇÕ´Ï´Ù. ĸ½¶Àº ¹æÃâ Á¦¾î¸¦ ¿ëÀÌÇÏ°Ô Çϰí Ä¡·á È¿°ú¸¦ Áö¼Ó½Ãŵ´Ï´Ù. Á¦¾à ȸ»ç´Â ȯÀÚÀÇ ÄÄÇöóÀÌ¾ð½º¿Í ¸¸Á·µµ¸¦ ³ôÀ̴ ĸ½¶ÀÇ Çõ½Å°ú »õ·Î¿î ó¹æ¿¡ ´ëÇÑ Å½±¸¸¦ À§ÇØ Á¡Â÷ ¿¬±¸ °³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

¿Â¶óÀÎ ¾à±¹ ºÎ¹®Àº 2023³âºÎÅÍ 2032³â±îÁö °­·ÂÇÑ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿Â¶óÀÎ ÀǾàǰ ±¸¸ÅÀÇ ÆíÀǼºÀº ÀüÀÚ»ó°Å·¡ÀÇ È®´ë¿Í ÇÔ²² ȯÀÚ°¡ °Ç°­ °ü¸®¿¡ Á¢±ÙÇÏ´Â ¹æ½ÄÀ» º¯È­½ÃÄ×½À´Ï´Ù. ¿Â¶óÀÎ ¾à±¹Àº ¿øÈ°ÇÑ ÁÖ¹®, Åùè, Æ®¶ó¸¶µ¹À» Æ÷ÇÔÇÑ ±¤¹üÀ§ÇÑ ÀǾàǰ¿¡ ´ëÇÑ ¾×¼¼½º¸¦ À§ÇÑ Ç÷§ÆûÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ Ã¤³ÎÀº ¿ø°Ý ÇコÄÉ¾î ¼­ºñ½º¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ¼±È£µµÀÇ ÁøÈ­¿¡ ´ëÀÀÇÒ »Ó¸¸ ¾Æ´Ï¶ó Á¢±Ù¼º°ú °¡°Ý °¨°¢À» ³ô¿© ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Æ®¶ó¸¶µ¹ ¾à¹° ½ÃÀåÀº ³ë³â Àα¸ Áõ°¡, ÅëÁõ °ü·Ã Áúȯ Áõ°¡·Î À̾îÁö´Â ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È­, ÀÌ Áö¿ªÀÇ °Ç°­ °ü¸® ÀÎÇÁ¶ó °³¼±À¸·Î 2032³â±îÁö Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ü°è°¡ ÁøÈ­Çϰí ÅëÁõ °ü¸®¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº Å©°Ô °³Ã´µÇ´Â ż¼¿¡ ÀÖÀ¸¸ç, Æ®¶ó¸¶µ¹ °ø±Þ¸Á Àüü¸¦ ÅëÇØ ÀÌÇØ°ü°èÀÚ¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Æ®¶ó¸¶µ¹ ¾à¹° ½ÃÀå ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ÅëÁõÁúȯ À¯º´·ü »ó½Â
      • ¿Ü°ú ¼ö¼ú °Ç¼ö Áõ°¡
      • ³ëÀÎ Àα¸ Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè ¹× °úÁ¦
      • ºÎ¼öÇÏ´Â ºÎÀÛ¿ë
      • ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØ
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå Æ®¶ó¸¶µ¹¾à ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Çüº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : Á¦Çüº°
  • Á¤Á¦
  • ĸ½¶Á¦
  • ¾×Á¦
  • Çöʾ×
  • ±âŸ Á¦Çü

Á¦6Àå Æ®¶ó¸¶µ¹¾à ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Åõ¿© °æ·Îº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : Åõ¿© °æ·Îº°
  • °æ±¸
  • ºñ°æ±¸
  • ±âŸ Åõ¿© °æ·Î

Á¦7Àå Æ®¶ó¸¶µ¹¾à ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Åë ä³Îº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : À¯Åë ä³Îº°
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå Æ®¶ó¸¶µ¹¾à ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Zydus Cadila
  • Purdue Pharma
  • Mankind Pharma Ltd
  • Mundipharma
  • Amneal Pharmaceuticals
  • Par Pharmaceuticals
  • Vertical Pharmaceuticals
  • Grunenthal Group
  • Nippon Shinyaku Co., Ltd
JHS 23.12.04

Tramadol drug market size is expected to record over 6.5% CAGR from 2023 to 2032, primarily fueled by an increasing prevalence of chronic pain conditions and a growing aging population globally. In 2022, there were nearly 771 million people above the age of 65 years across the globe, which is almost 10% of the total population. This proportion will reach around 16% of the world's population by 2050.

With a rising awareness of pain management therapies, tramadol has emerged as a preferred choice of treatment among healthcare practitioners and patients alike. The drug's versatile nature, offering both immediate-release and extended-release formulations, positions it as a valuable tool in addressing a spectrum of pain intensities. As healthcare providers strive to enhance patient outcomes and minimize opioid-related risks, the product's unique profile will contribute to the market growth.

The tramadol drug industry is classified based on dosage form, route of administration, distribution channel, and region.

The capsule segment is predicted to witness substantial demand through 2032 as it is a preferred choice for both prescribers and patients. Capsules provide a convenient and effective means of administering tramadol, ensuring precise dosing and ease of use. They facilitate controlled release, offering a sustained therapeutic effect. Pharmaceutical companies are increasingly investing in R&D to innovate and explore novel formulations with capsules that enhance patient compliance and satisfaction.

The online pharmacy segment is anticipated to record strong CAGR from 2023 to 2032. The convenience of purchasing medications online, coupled with an expanding e-commerce landscape, has revolutionized the way patients access healthcare. Online pharmacies provide a platform for seamless ordering, home delivery, and access to a wide range of pharmaceutical products, including tramadol. This channel not only caters to the evolving consumer preferences for remote healthcare services but also fosters market growth by enhancing accessibility and affordability.

Asia Pacific tramadol drug market will grow significantly through 2032 due to the rising geriatric population, changing lifestyles leading to increased pain-related disorders, and improving healthcare infrastructure in the region. As regulatory frameworks evolve and awareness of pain management grows, the Asia Pacific market is poised for significant development, presenting lucrative opportunities for stakeholders across the tramadol supply chain.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market definition
  • 1.2 Base estimates & calculations
  • 1.3 Forecast calculation
  • 1.4 Covid-19 impact analysis at global level
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Global tramadol drug market 360 degree synopsis, 2018 - 2032 (USD Million)
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Dosage form trends
    • 2.1.4 Route of administration trends
    • 2.1.5 Distribution channel trends

Chapter 3 Tramadol Drug Market Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of pain disorders
      • 3.2.1.2 Rising number of surgical procedures
      • 3.2.1.3 Increasing geriatric population
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Associated side effects
      • 3.2.2.2 Strict regulatory norms
  • 3.3 Growth potential analysis
    • 3.3.1 By dosage form
    • 3.3.2 By route of administration
    • 3.3.3 By distribution channel
  • 3.4 COVID-19 impact analysis
  • 3.5 Regulatory landscape
    • 3.5.1 U.S.
    • 3.5.2 Europe
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard, 2022

Chapter 5 Tramadol Drug Market Size and Forecast, By Dosage Form, 2018 - 2032 (USD Million)

  • 5.1 Key trends, by dosage form
  • 5.2 Tablet
  • 5.3 Capsule
  • 5.4 Liquid
  • 5.5 Suspension
  • 5.6 Other dosage forms

Chapter 6 Tramadol Drug Market Size and Forecast, By Route of Administration, 2018 - 2032 (USD Million)

  • 6.1 Key trends, by route of administration
  • 6.2 Oral
  • 6.3 Parenteral
  • 6.4 Other routes of administration

Chapter 7 Tramadol Drug Market Size and Forecast, By Distribution Channel, 2018 - 2032 (USD Million)

  • 7.1 Key trends, by distribution channel
  • 7.2 Hospital pharmacy
  • 7.3 Retail pharmacy
  • 7.4 Online pharmacy

Chapter 8 Tramadol Drug Market Size and Forecast, By Region, 2018 - 2032 (USD Million)

  • 8.1 Key trends, by region
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East & Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 Rest of Middle East & Africa

Chapter 9 Company Profiles

  • 9.1 Zydus Cadila
  • 9.2 Purdue Pharma
  • 9.3 Mankind Pharma Ltd
  • 9.4 Mundipharma
  • 9.5 Amneal Pharmaceuticals
  • 9.6 Par Pharmaceuticals
  • 9.7 Vertical Pharmaceuticals
  • 9.8 Grunenthal Group
  • 9.9 Nippon Shinyaku Co., Ltd
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦